CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing therapies to prevent cell death in the optic nerve, particularly in conditions like glaucoma. It aims to inhibit the protein Semaphorin 3A to promote neural regeneration and protect retinal cells.
The visual pathway is a component of the central nervous system (CNS) and therefore is not regenerative.
Acute optic nerve injury, ischemic optic neuropathy and glaucoma are conditions that initially lead to partial blindness and eventually could lead to total blindness.
Extensive neuron and retinal ganglion cells (RGC) death is evidenced in these pathologies.
Semaphorin 3A (Sema3A) is a cell secreted protein that participates in the axonal guidance pathways.
Partner TAU was the first to show th…
TEL AVIV UNIVERSITY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Israel, LOD
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, Tuebingen
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Spain, Barcelona
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
